

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended) A method for treating a patient suffering from a breast or ovarian cancerous disease comprising:

administering to said patient an ~~anti-cancer~~ isolated monoclonal antibody or antigen binding fragment thereof produced in accordance with a method for the production of anti-cancer antibodies which are useful in treating [[a]] said breast or ovarian cancerous disease, said isolated monoclonal antibody or antigen binding fragment thereof characterized as being cytotoxic against cells of [[a]] said cancerous tissue, ~~and being essentially benign to non-cancerous cells;~~

wherein said isolated monoclonal antibody or antigen binding fragment thereof is placed in admixture with a pharmaceutically acceptable adjuvant and is administered in an amount effective to mediate treatment of said cancerous disease;

said antibody being an isolated monoclonal antibody or antigen binding fragment thereof which binds to [[an]] the ^{same epitope} ~~antigenic moiety~~ expressed by said cancerous tissue, ~~said antigenic moiety characterized as being~~ which is bound by an antibody having the

~~identifying characteristics of a~~ the isolated monoclonal antibody
~~encoded by a clone~~ produced by a hybridoma deposited with the ATCC
as PTA-5643.

Claim 2. (Currently Amended) The method for treating a
patient suffering from ~~[[a]]~~ said cancerous disease in accordance
with claim 1, wherein said isolated monoclonal antibody ~~or antigen~~
~~binding fragment thereof~~ is a humanized ~~or~~ chimerized ~~chimeric~~
antibody of the isolated monoclonal antibody produced by the
hybridoma deposited with the ATCC under accession number PTA-5643.

Claim 3. (Currently Amended) The method for treating a
patient suffering from ~~[[a]]~~ said cancerous disease in accordance
with claim 1 comprising:

conjugating said isolated monoclonal antibody or antigen
binding fragment thereof with a member selected from the group
consisting of toxins, ~~enzymes~~, radioactive compounds, and
hematogenous cells, thereby forming an antibody conjugate; and

administering said antibody conjugate or conjugated antigen
binding fragments to said patient;

wherein said antibody conjugate or antigen binding conjugated fragments are placed in admixture with a pharmaceutically acceptable adjuvant and are administered in an amount effective to mediate treatment of said cancerous disease.

Claim 4. (Currently Amended) The method of claim 3, wherein said isolated monoclonal antibody ~~or fragment thereof~~ is a humanized ~~or~~ chimerized chimeric antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC under accession number PTA-5643.

Claim 5. (withdrawn) The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the cytotoxicity of said ~~antibody~~ or fragment thereof is mediated through antibody dependent cellular toxicity.

Claim 6. (withdrawn) The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the cytotoxicity of said ~~antibody~~ or fragment thereof is mediated through complement dependent cellular toxicity.

Claim 7. (withdrawn) The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the cytotoxicity of said antibody or fragment thereof is mediated through catalyzing of the hydrolysis of cellular chemical bonds.

Claim 8. (withdrawn) The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the cytotoxicity of said antibody or fragment thereof is mediated through producing an immune response against putative cancer antigens residing on tumor cells.

Claim 9. (withdrawn) The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the cytotoxicity of said antibody or fragment thereof is mediated through targeting of cell membrane proteins to interfere with their function.

Claim 10. (Cancelled)

5
Claim 11. (original) The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

is performed with
said method of production ~~utilizes~~ a tissue sample containing cancerous and non-cancerous cells obtained from ~~a particular~~ ^{said patient} individual.

6
Claim 12. (Currently Amended) A method for treating a patient suffering from [[a]] a breast or ovarian cancerous disease comprising:

administering to said patient an isolated monoclonal antibody or antigen binding fragment thereof produced in accordance with a method for the production of ~~anti-cancer~~ antibodies which are useful in treating [[a]] said cancerous disease, said antibody being cytotoxic against cells of [[a]] said cancerous tissue, ~~and essentially benign to non-cancerous cells;~~

wherein said antibody is the isolated monoclonal antibody ~~encoded by the clone produced by the hybridoma~~ deposited with the ATCC as PTA-5643 or an antigen binding fragment thereof~~[[,]]~~; and

wherein said isolated monoclonal antibody or antigen binding fragment is placed in admixture with a pharmaceutically acceptable adjuvant and is administered in an amount effective to mediate treatment of said cancerous disease.

Claim ~~13~~⁷. (Currently Amended) The method for treating a patient suffering from a cancerous disease in accordance with claim ~~6~~⁷, wherein said isolated monoclonal antibody ~~or fragment thereof~~ is a humanized ~~or~~ chimerized ~~chimeric~~ antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC under accession number PTA-5643.

Claim ~~14~~⁸. (Currently Amended) The method for treating a patient suffering from a cancerous disease in accordance with claim ~~6~~¹² comprising:

conjugating said isolated monoclonal antibody or antigen binding fragment thereof with a member selected from the group consisting of toxins, ~~enzymes~~, radioactive compounds, and hematogenous cells, whereby an antibody conjugate is formed; and administering said antibody conjugates or antigen binding fragments thereof to said patient;

wherein said conjugated antibodies or antigen binding fragments thereof are placed in admixture with a pharmaceutically acceptable adjuvant and are administered in an amount effective to mediate treatment of said cancerous disease.

Claim ⁹~~15~~. (Currently Amended) The method of claim ⁸~~14~~, wherein said isolated monoclonal antibody ~~or fragment thereof~~ is a humanized ~~or~~ chimerized ~~chimeric~~ antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC under accession number PTA-5643.

Claim 16. (withdrawn) The method for treating a patient suffering from a cancerous disease in accordance with claim 12 wherein:

the cytotoxicity of said antibody or fragment thereof is mediated through antibody dependent cellular toxicity.

Claim 17. (withdrawn) The method for treating a patient suffering from a cancerous disease in accordance with claim 12 wherein:

the cytotoxicity of said antibody or fragment thereof is mediated through complement dependent cellular toxicity.

Claim 18. (withdrawn) The method for treating a patient suffering from a cancerous disease in accordance with claim 12 wherein:

the cytotoxicity of said antibody or fragment thereof is mediated through catalyzing of the hydrolysis of cellular chemical bonds.

Claim 19. (withdrawn) The method for treating a patient suffering from a cancerous disease in accordance with claim 12 wherein:

the cytotoxicity of said antibody or fragment thereof is mediated through producing an immune response against putative cancer antigens residing on tumor cells.

Claim 20. (withdrawn) The method for treating a patient suffering from a cancerous disease in accordance with claim 12 wherein:

the cytotoxicity of said antibody or fragment thereof is mediated through targeting of cell membrane proteins to interfere with their function.

Claim 21. (Cancelled)

Claim ¹⁰~~22~~. (original) The method for treating a patient suffering from a cancerous disease in accordance with claim ~~22~~ ⁶ wherein:

said method of production ^{is performed with} utilizes a tissue sample containing cancerous and non-cancerous cells obtained from ^{said patient} ~~a particular~~ individual.

Claim 23. (Currently Amended) A process for mediating cytotoxicity of a human breast or ovarian tumor cell which expresses an MCSP antigenic moiety on the cell surface which moiety is bound by the isolated monoclonal antibody produced by a hybridoma deposited with the ATCC as PTA-5643 comprising:

contacting said breast or ovarian tumor cell with an isolated monoclonal antibody or antigen binding fragment thereof, ~~said antibody or antigen binding fragment thereof being an isolated monoclonal antibody or antigen binding fragment thereof~~ which binds to said expressed MCSP antigenic moiety, ~~said antigenic moiety characterized as being bound by an antibody having the identifying characteristics of a monoclonal antibody encoded by the clone deposited with the ATCC as PTA-5643,~~

whereby cell cytotoxicity occurs as a result of said binding.

Claim 24. (Currently Amended) The process of claim 23 wherein said isolated monoclonal antibody or ~~antigen binding fragment thereof~~ is a humanized or chimerized chimeric antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC under accession number PTA-5643.

Claim 25. (Currently Amended) The process of claim 23 wherein said isolated monoclonal antibody or antigen binding fragments thereof are conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells, whereby an antibody conjugate is formed.

Claim 26. (Currently Amended) The process of claim 25 wherein said isolated monoclonal antibody or antigen binding fragments thereof is a humanized or chimerized chimeric antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC under accession number PTA-5643.

Claim 27. (Cancelled)

Claim 28. (Currently Amended) The process of claim 23 wherein [[the]] said human tumor cell ~~tissue sample~~ is obtained from a tumor originating in a ~~tissue selected from the group consisting of~~ breast tissue.

Claim 29. (Cancelled)

Claim 30. (withdrawn) The binding assay of claim 29 wherein the cell sample is obtained from a tumor originating in a tissue selected from the group consisting of breast tissue.

Claim 31. (Cancelled)

Claim 32. (withdrawn) The process of claim 31 wherein the cell sample is obtained from a tumor originating in a tissue selected from the group consisting of breast tissue.

Claim 33. (withdrawn) A method of extending survival and/or delaying disease progression by treating a human tumor in a mammal, wherein said tumor expresses an antigen which specifically binds to a monoclonal antibody or antigen binding fragment thereof which has the identifying characteristics of a monoclonal antibody encoded by a clone deposited with the ATCC as accession number PTA-

5643 comprising administering to said mammal said monoclonal antibody in an amount effective to reduce said mammal's tumor burden, whereby disease progression is delayed and/or survival is extended.

Claim 34. (withdrawn) The method of claim 33 wherein said antibody is conjugated to a cytotoxic moiety.

Claim 35. (withdrawn) The method of claim 33 wherein said cytotoxic moiety is a radioactive isotope.

Claim 36. (withdrawn) The method of claim 33 wherein said antibody activates complement.

Claim 37. (withdrawn) The method of claim 33 wherein said antibody mediates antibody dependent cellular cytotoxicity.

Claim 38. (withdrawn) The method of claim 33 wherein said antibody is a murine antibody.

Claim 39. (withdrawn) The method of claim 33 wherein said antibody is a humanized antibody.

Claim 40. (withdrawn) The method of claim 33 wherein said antibody is a chimerized antibody.